Clairity has concluded a $43m funding round, setting the company up to advance commercialisation efforts for its AI-powered breast cancer prediction platform.
The US-based company’s Series B funding round was led by VC companies ACE Global Equity and Santé Ventures. Existing investor, the Breast Cancer Research Foundation (BCRF) and several new investors also participated.
Clairity’s lead product is Clairity Breast, a platform that is designed to estimate a woman’s five-year breast cancer risk directly from routine mammograms. According to the company, the platform analyses subtle imaging features on screening mammograms that correlate with future breast cancer risk.
The overall rationale behind the platform, which received a de novo classification from the US Food and Drug Administration (FDA) in June 2025, is to shift care from detection to prevention.
Clairity intends to use the fresh funds to advance Clairity Breast’s commercialisation efforts in the US. It will begin by focusing on rollouts across leading imaging centres and healthcare systems, while also exploring reimbursement initiatives to bring the platform to community imaging centres.
Clairity’s CEO Jeff Luber said: “With FDA authorisation in hand and commercial partnerships underway, Clairity Breast is poised to redefine how the world approaches breast cancer.
“We’re proud to stand at the forefront of a paradigm shift - from detection to prevention - and to deliver technology that empowers women and their doctors to predict risk to support action before cancer starts.”
Early detection of breast cancer, which is the most commonly diagnosed cancer in women worldwide, significantly increases the chances of successful treatment and survival, with the stage of the cancer at the time of diagnosis strongly correlated with patient outcomes. According to GlobalData analysis, community outreach should be prioritised to bring awareness to anyone who may be affected by breast cancer.
Looking ahead, Clairity said a portion of the tranche would also be used to advance its pipeline to include new AI-based predictive offerings for other major diseases, by applying the same deep learning framework on which Clairity Breast was built.
AI continues to have a significant impact in the medical imaging space. According to GlobalData analysis, the use of AI across healthcare is rapidly advancing, with the market projected to reach a $19bn valuation by 2027. Imaging software developer DeepLook Medical is one of those in the space.
Speaking with Medical Device Network at Life Sciences Baltics 2025 in Vilnius, Lithuania in September, DeepLook Medical’s CEO Marissa Fayer described the application of AI in imaging as “endless”. She highlighted that looking ahead, the technology will likely continue expanding into areas such as fully-fledged decision-making, interpretation, and longitudinal forecasting.
